Skip to main content

Advertisement

SpringerLink
Log in

[68Ga]-Pentixafor PET/CT imaging of lymphoproliferative malignancies

  • Pictorial Essay
  • Published:
Clinical and Translational Imaging Aims and scope Submit manuscript

Abstract

Purpose

This report evaluates [68Ga]-Pentixafor and [18F]-FDG PET/CT uptake patterns of patients with lymphoproliferative malignancies.

Methods

Patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukaemia (CLL) who underwent [18F]-FDG PET/CT for staging followed by [68Ga]-Pentixafor PET/CT within 1 week were retrospectively evaluated. Patterns of [18F]-FDG and [68Ga]-Pentixafor uptake characteristics were described in histopathologically confirmed patients.

Results

Two patients with CLL, five with B-cell lymphomas, and four with T-cell lymphomas , with a mean age of 56.8 years (range 22–80), were included in this study. Four B-cell lymphoma patients were [18F]-FDG and [68Ga]-Pentixafor positive, whereas one patient was only [18F]-FDG-positive. [68Ga]-Pentixafor uptake in two patients and [18F]-FDG uptake in one patient was higher than the other, and one patient demonstrated a heterogeneous uptake pattern with flip-flop tracer uptake. Aggressive transformation to lymphoma in one CLL patient was presented with mild [68Ga]-Pentixafor uptake in the [18F]-FDG-positive lymph nodes. The other CLL patient had mild [18F]-FDG uptake and no [68Ga]-Pentixafor uptake in the lymph nodes, but bone marrow involvement was only detected by [68Ga]-Pentixafor PET/CT. Three of four patients with T-cell lymphoma patients demonstrated [18F]-FDG and [68Ga]-Pentixafor uptake, and one patient was only positive on [18F]-FDG PET/CT.

Conclusion

Our results demonstrate [68Ga]-Pentixafor uptake in different subtypes of NHL and CLL; however, the potential complementary role of [68Ga]-Pentixafor PET/CT towards personalized diagnostic concepts remains yet to be determined by further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Balkwill F (2004) Cancer and the chemokine network. Nat Rev Cancer 4(7):540–550. https://doi.org/10.1038/nrc1388

    Article  CAS  PubMed  Google Scholar 

  2. Mayerhoefer ME, Jaeger U, Staber P, Raderer M, Wadsak W, Pfaff S, Kornauth C, Senn D, Weber M, Wester HJ, Skrabs C, Haug A (2018) [68Ga]Ga-Pentixafor PET/MRI for CXCR4 imaging of chronic lymphocytic leukemia: preliminary results. Invest Radiol 53(7):403–408. https://doi.org/10.1097/RLI.0000000000000469

    Article  CAS  PubMed  Google Scholar 

  3. Pan Q, Luo Y, Zhang Y, Chang L, Li J, Cao X, Li J, Li F (2020) Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [(68)Ga]pentixafor in non-Hodgkin lymphoma: comparison to [(18)F]FDG. EJNMMI Res 10(1):89. https://doi.org/10.1186/s13550-020-00681-7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Duell J, Krummenast F, Schirbel A, Klassen P, Samnick S, Rauert-Wunderlich H, Rasche L, Buck AK, Wester HJ, Rosenwald A, Einsele H, Topp MS, Lapa C, Kircher M (2021) Improved primary staging of marginal zone lymphoma by addition of CXCR4-directed PET/CT. J Nucl Med. https://doi.org/10.2967/jnumed.120.257279

    Article  PubMed  Google Scholar 

  5. Herhaus P, Lipkova J, Lammer F, Yakushev I, Vag T, Slotta-Huspenina J, Habringer S, Lapa C, Pukrop T, Hellwig D, Wiestler B, Buck AK, Deckert M, Wester HJ, Bassermann F, Schwaiger M, Weber W, Menze B, Keller U (2020) CXCR4-targeted PET imaging of central nervous system B cell lymphoma. J Nucl Med 61(12):1765–1771. https://doi.org/10.2967/jnumed.120.241703

    Article  CAS  PubMed  Google Scholar 

  6. Mayerhoefer ME, Raderer M, Lamm W, Pichler V, Pfaff S, Weber M, Kiesewetter B, Hacker M, Kazianka L, Staber PB, Wester HJ, Rohrbeck J, Simonitsch-Klupp I, Haug A (2021) CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]pentixafor: comparison with [(18)F]FDG-PET. Theranostics 11(2):567–578. https://doi.org/10.7150/thno.48620

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Starzer AM, Berghoff AS, Traub-Weidinger T, Haug AR, Widhalm G, Hacker M, Rausch I, Preusser M, Mayerhoefer ME (2021) Assessment of central nervous system lymphoma based on CXCR4 expression in vivo using 68Ga-pentixafor PET/MRI. Clin Nucl Med 46(1):16–20. https://doi.org/10.1097/rlu.0000000000003404

    Article  PubMed  PubMed Central  Google Scholar 

  8. Kuyumcu S, Isik EG, Tiryaki TO, Has-Simsek D, Sanli Y, Buyukkaya F, Ozkan ZG, Kalayoglu-Besisik S, Unal SN (2021) Prognostic significance of (68)Ga-pentixafor PET/CT in multiple myeloma recurrence: a comparison to (18)F-FDG PET/CT and laboratory results. Ann Nucl Med. https://doi.org/10.1007/s12149-021-01652-1

    Article  PubMed  Google Scholar 

  9. Isik EG, Kuyumcu S, Kebudi R, Sanli Y, Karakas Z, Cakir FB, Unal SN (2017) Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of (18)FDG-PET/CT according to DeltaSUVmax, Deauville 5-point scale and IHP criteria. Ann Nucl Med 31(9):660–668. https://doi.org/10.1007/s12149-017-1196-x

    Article  CAS  PubMed  Google Scholar 

  10. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R, Israel O (2010) (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51(1):25–30. https://doi.org/10.2967/jnumed.109.067892

    Article  PubMed  Google Scholar 

  11. Albano D, Laudicella R, Ferro P, Allocca M, Abenavoli E, Buschiazzo A, Castellino A, Chiaravalloti A, Cuccaro A, Cuppari L, Durmo R, Evangelista L, Frantellizzi V, Kovalchuk S, Linguanti F, Santo G, Bauckneht M, Annunziata S (2019) The role of 18F-FDG PET/CT in staging and prognostication of mantle cell lymphoma: an Italian multicentric study. Cancers 11(12):1831

    Article  CAS  PubMed Central  Google Scholar 

  12. Albano D, Treglia G, Gazzilli M, Cerudelli E, Giubbini R, Bertagna F (2020) 18F-FDG PET or PET/CT in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 20(7):422–430. https://doi.org/10.1016/j.clml.2020.01.018

    Article  PubMed  Google Scholar 

  13. Albano D, Camoni L, Rodella C, Giubbini R, Bertagna F (2021) 2-[18F]-FDG PET/CT role in detecting richter transformation of chronic lymphocytic leukemia and predicting overall survival. Clin Lymphoma Myeloma Leuk 21(3):e277–e283. https://doi.org/10.1016/j.clml.2020.12.003

    Article  PubMed  Google Scholar 

  14. Albano D, Durmo R, Treglia G, Giubbini R, Bertagna F (2020) (18)F-FDG PET/CT or PET Role in MALT lymphoma: an open issue not yet solved-a critical review. Clin Lymphoma Myeloma Leuk 20(3):137–146. https://doi.org/10.1016/j.clml.2019.10.006

    Article  PubMed  Google Scholar 

  15. Haug AR, Leisser A, Wadsak W, Mitterhauser M, Pfaff S, Kropf S, Wester HJ, Hacker M, Hartenbach M, Kiesewetter-Wiederkehr B, Raderer M, Mayerhoefer ME (2019) Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI. Theranostics 9(12):3653–3658. https://doi.org/10.7150/thno.31032

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Feeney J, Horwitz S, Gonen M, Schoder H (2010) Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol 195(2):333–340. https://doi.org/10.2214/AJR.09.3665

    Article  PubMed  Google Scholar 

  17. Weng AP, Shahsafaei A, Dorfman DM (2003) CXCR4/CD184 immunoreactivity in T cell non-Hodgkin lymphomas with an overall Th1- Th2+ immunophenotype. Am J Clin Pathol 119(3):424–430. https://doi.org/10.1309/rf4pvceggn2xaf86

    Article  PubMed  Google Scholar 

  18. Kuyumcu S, Yilmaz E, Buyukkaya F, Ozkan ZG, Unal SN (2018) Imaging of chemokine receptor CXCR4 in mycosis fungoides using 68Ga-pentixafor PET/CT. Clin Nucl Med 43(8):606–608. https://doi.org/10.1097/Rlu.0000000000002166

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Istanbul Medical Faculty, 34093, Fatih, Istanbul, Turkey

    Serkan Kuyumcu, Murat Yilmaz Kıran & Yasemin Şanlı

  2. Department of Pathology, Istanbul Medical Faculty, Istanbul, Turkey

    Evşen Apaydın Arıkan & Gülçin Yeğen

Authors
  1. Serkan Kuyumcu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Murat Yilmaz Kıran
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Evşen Apaydın Arıkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gülçin Yeğen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yasemin Şanlı
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SK: literature search, content planning, patient evaluation manuscript writing and editing; MYK: image acquisition, preparation of figures and literature review; EAA: writing of pathological findings and literature review, preparation of pathology figures; GY: writing of pathological findings and literature review, preparation of pathology figures; YS: patient evaluation manuscript writing and editing, literature review.

Corresponding author

Correspondence to Serkan Kuyumcu.

Ethics declarations

Conflict of interest

The authors declare no conflict of interest.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/ or national research committee and with the 1964 Helsinki Declaration and its later amendments.

Informed consent

All patients gave written informed consent for [68Ga]-Pentixafor PET/CT imaging and publication of their medical data.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kuyumcu, S., Kıran, M.Y., Apaydın Arıkan, E. et al. [68Ga]-Pentixafor PET/CT imaging of lymphoproliferative malignancies. Clin Transl Imaging 9, 641–648 (2021). https://doi.org/10.1007/s40336-021-00458-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40336-021-00458-5

Keywords

Search

Navigation